Chen Ningxin, Li Ruikun, Jiang Mengmeng, Guo Yixian, Chen Jiejun, Sun Dazhen, Wang Lisheng, Yao Xiuzhong
Department of Radiology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Department of Automation, Shanghai Jiao Tong University, Shanghai, China.
Front Med (Lausanne). 2022 Feb 24;9:833283. doi: 10.3389/fmed.2022.833283. eCollection 2022.
The aim of this study was to predict the progression-free survival (PFS) in patients with small cell lung cancer (SCLC) by radiomic signature from the contrast-enhanced computed tomography (CT).
A total of 186 cases with pathological confirmed small cell lung cancer were retrospectively assembled. First, 1,218 radiomic features were automatically extracted from tumor region of interests (ROIs) on the lung window and mediastinal window, respectively. Then, the prognostic and robust features were selected by machine learning methods, such as (1) univariate analysis based on a Cox proportional hazard (CPH) model, (2) redundancy removing using the variance inflation factor (VIF), and (3) multivariate importance analysis based on random survival forests (RSF). Finally, PFS predictive models were established based on RSF, and their performances were evaluated using the concordance index (C-index) and the cumulative/dynamic area under the curve (C/D AUC).
In total, 11 radiomic features (6 for mediastinal window and 5 for lung window) were finally selected, and the predictive model constructed from them achieved a C-index of 0.7531 and a mean C/D AUC of 0.8487 on the independent test set, better than the predictions by single clinical features (C-index = 0.6026, mean C/D AUC = 0.6312), and single radiomic features computed in lung window (C-index = 0.6951, mean C/D AUC = 0.7836) or mediastinal window (C-index = 0.7192, mean C/D AUC = 0.7964).
The radiomic features computed from tumor ROIs on both lung window and mediastinal window can predict the PFS for patients with SCLC by a high accuracy, which could be used as a useful tool to support the personalized clinical decision for the diagnosis and patient management of patients with SCLC.
本研究旨在通过对比增强计算机断层扫描(CT)的放射组学特征预测小细胞肺癌(SCLC)患者的无进展生存期(PFS)。
回顾性收集了186例经病理证实的小细胞肺癌病例。首先,分别从肺窗和纵隔窗的肿瘤感兴趣区域(ROI)自动提取1218个放射组学特征。然后,通过机器学习方法选择预后和稳健特征,例如:(1)基于Cox比例风险(CPH)模型的单变量分析;(2)使用方差膨胀因子(VIF)去除冗余;(3)基于随机生存森林(RSF)的多变量重要性分析。最后,基于RSF建立PFS预测模型,并使用一致性指数(C指数)和曲线下累积/动态面积(C/D AUC)评估其性能。
最终共选择了11个放射组学特征(纵隔窗6个,肺窗5个),由这些特征构建的预测模型在独立测试集上的C指数为0.7531,平均C/D AUC为0.8487,优于单一临床特征的预测结果(C指数 = 0.6026,平均C/D AUC = 0.6312),以及在肺窗(C指数 = 0.6951,平均C/D AUC = 0.7836)或纵隔窗(C指数 = 0.7192,平均C/D AUC = 0.7964)计算的单一放射组学特征。
从肺窗和纵隔窗的肿瘤ROI计算出的放射组学特征能够高精度地预测SCLC患者的PFS,可作为支持SCLC患者诊断和患者管理个性化临床决策的有用工具。